Polycaprolactone microsphere pre-dispersed composition and polycaprolactone injectable GEL prepared from same
Patent Information
- Application Number
- MYPI2025001925
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-30
- Filing Date
- 2023-08-25
- Publication Date
- 2024-03-30
AI Technical Summary
When dispersing polycaprolactone microspheres into gels with the existing technology, it is difficult to maintain the surface smoothness and dispersion of the microspheres, and hydrolysis causes degradation problems, affecting the stability and safety of the product.
Phosphate buffer is used as the dispersion medium, and the degradation rate of the microspheres is significantly reduced by adjusting the pH value and osmotic pressure. The dry microspheres are evenly dispersed into the gel through the method of pre-dispersing the composition to reduce the formation of bubbles.
It effectively maintains the spherical integrity and surface smoothness of the microspheres, reduces the degradation rate of the microspheres, improves the dispersion and stability of the product, and reduces the occurrence of nodules and granulomas after injection.
Smart Images

Figure PI2025001925_DRAWING_001 
Figure PI2025001925_DRAWING_002 
Figure PI2025001925_DRAWING_003
Abstract
Description
A polycaprolactone microsphere pre-dispersed composition and a polycaprolactone injection gel prepared therefrom Technical Field
[0001] The present invention relates to the technical field of medical cosmetology or medical preparations, and in particular to a polycaprolactone microsphere pre-dispersed composition and a polycaprolactone injection gel prepared therefrom. Background Art
[0002] Polycaprolactone (PCL) was first synthesized in the 1930s. It is a linear aliphatic polyester obtained by the ring-opening polymerization of ε-caprolactone (ε-CL). It is a hydrophobic, semi-crystalline polymer that is in a rubbery state at room temperature. It has good thermal stability and a decomposition temperature much higher than other polyesters. The products of PCL degradation are CO2 and H2O, which are non-toxic to the human body. Due to its specific physicochemical and mechanical properties, viscoelasticity and ease of molding, PCL-based products with various shapes and durations are produced, depending on its biodegradation kinetics. PCL has been safely used in the biomedical field for over 70 years. The latest applications are to prepare it into microspheres for use as medical aesthetic fillers for in vivo implantation materials to stimulate collagen production. PCL-based collagen stimulators are composed of PCL microspheres suspended in a carboxymethyl cellulose gel carrier, which can provide immediate and sustained plumping effects when injected; the morphology and biocompatibility of the PCL microspheres embedded in the generated collagen fibers help create a unique 3D scaffold to achieve a sustained effect.
[0003] With the growing demand for medical aesthetics, PCL has a broader market prospect. PCL is primarily formulated into microspheres and applied in a gel format to the forehead, nasolabial folds, midface, nose, chin, and hands. Its effectiveness can last up to 24 months, and its safety and efficacy have been demonstrated in multiple clinical trials. PCL injectable microspheres typically have a diameter of 25-50 μm, a size ideal for evading macrophage phagocytosis and remaining in tissue. Not only size but also shape has been shown to significantly influence tissue response, with the degree of response determined by shape, whether round or irregular. PCL microspheres are regular, spherical with a smooth surface, characteristics known to minimize inflammatory responses. Smoother spheres are more suitable for subcutaneous injection. Highly smooth microspheres stimulate the fibroblasts beneath wrinkles to encapsulate them, reducing the development of granulomas and the likelihood of a foreign body reaction. Injectable microspheres are typically prepared by evenly suspending 30% by volume of smooth PCL microspheres in a 70% CMC gel.
[0004] Several methods for preparing PCL microspheres with smooth surfaces have been disclosed in the prior art. For example, CN104001209B discloses filtering, washing, and drying the resulting microspheres before dispersing them into a CMC gel. To prevent solidification of the PCL solution in a stirred aqueous medium, the preparation process employs conditions such as adding a PCL solution in DCM over a prolonged period and allowing the DCM to evaporate for a long time, thereby hardening the dispersed PCL particles. The document also examines the Hunter method (Example 14 in US2003 / 0157187A) and the Erneta and Wu method (Examples in EP1872803A1), and summarizes the effects of DCM, surfactants in water, surfactant viscosity, and stirring rate on particle shape and surface smoothness. CN109998997B discloses microspheres prepared by a membrane emulsification method. After filtration, washing, and drying, the microspheres have an average diameter of 50 μm and exhibit a smooth, well-formed appearance. However, in order to disperse the prepared dry microspheres into the gel and maintain the smoothness of the surface in the gel, further research is needed on the dispersion process of the microspheres and the gel. Before the PCL microspheres are mixed into the CMC gel, some air will be adsorbed on the surface. During the mixing process, there is a problem that the liquid and gas begin to compete for the surface of the microspheres, making it difficult to remove the bubbles on the surface of the microspheres. In addition, due to the high viscosity of the CMC gel, the PCL microspheres are not easy to disperse and are prone to forming bubbles during the mixing process. Therefore, a new method is needed to solve the above problems during the mixing process. Moreover, the study found that the hydrolysis of PCL microspheres is related to the penetration of water into the microspheres. When water penetrates the microspheres, an overall degradation process occurs, causing the ester bonds in the entire polymer matrix to gradually hydrolyze from the inside. Therefore, further research is needed on the dispersion process of the microspheres and the basis of the gel to promote the PCL microspheres prepared to still have a smooth surface in the gel and to further reduce the hydrolysis of PCL.
[0005] Summary of the Invention
[0006] To overcome the shortcomings of the prior art, the present invention provides a pre-dispersed polycaprolactone (PCL) microsphere composition and an injectable gel containing a high concentration of polycaprolactone prepared using this composition. Through research, the inventors unexpectedly discovered that the mixing or redispersion of the PCL microspheres after drying is a key factor affecting the dispersion, bubble formation, and smoothness of the injectable PCL microspheres. Furthermore, the inventors unexpectedly discovered that, compared to the commonly used PCL microsphere dispersion media in the prior art—purified water, distilled water, physiological saline, etc.—the dispersion medium and gel matrix selected in the present invention can effectively reduce PCL degradation. Maintaining the smooth spherical shape of the microspheres helps reduce the degradation rate of the microspheres.
[0007] In a first aspect of the present invention, a polycaprolactone microsphere pre-dispersed composition is provided, comprising polycaprolactone microspheres and phosphate buffer.
[0008] Specifically, the phosphate buffer comprises dihydrogen phosphate and / or dihydrogen phosphate; more specifically, the phosphate buffer comprises dihydrogen phosphate and dihydrogen phosphate.
[0009] Specifically, the disalt of hydrogen phosphate is selected from one or more of disodium hydrogen phosphate, dipotassium hydrogen phosphate, and diammonium hydrogen phosphate.
[0010] Specifically, the dihydrogen phosphate is selected from one or more of sodium dihydrogen phosphate, potassium dihydrogen phosphate or ammonium dihydrogen phosphate.
[0011] In some embodiments of the present invention, the disalt of hydrogen phosphate is disodium hydrogen phosphate, and the dihydrogen phosphate is sodium dihydrogen phosphate.
[0012] In other embodiments of the present invention, the disalt of hydrogen phosphate is disodium hydrogen phosphate, and the dihydrogen phosphate is potassium dihydrogen phosphate.
[0013] In other embodiments of the present invention, the dihydrogen phosphate is dipotassium hydrogen phosphate, and the dihydrogen phosphate is potassium dihydrogen phosphate.
[0014] In other embodiments of the present invention, the disalt of hydrogen phosphate is dipotassium hydrogen phosphate, and the disalt of dihydrogen phosphate is sodium dihydrogen phosphate.
[0015] Specifically, the phosphate buffer may further include a pH adjuster, such as one or more of hydrochloric acid, sodium hydroxide, potassium hydroxide, and the like.
[0016] Specifically, the pH of the phosphate buffer is 6.0-8.0 (e.g., 6.0, 6.2, 6.4, 6.5, 6.6, 6.8, 7.0, 7.2, 7.4, 7.5, 7.6, 7.8, 8.0), in particular 6.5-8.0, preferably 7.0-7.5.
[0017] Specifically, the phosphate buffer may further include an osmotic pressure regulator, such as one or more of potassium chloride, sodium chloride, glycerol, and the like.
[0018] Specifically, the osmotic pressure of the phosphate buffer is 300-700 mOsm / kg (e.g., 300, 350, 400, 450, 500, 550, 600 mOsm / kg), particularly 500-650 mOsm / kg, preferably 550-650 mOsm / kg.
[0019] In some preferred embodiments of the present invention, the phosphate buffer comprises disodium hydrogen phosphate and sodium dihydrogen phosphate, has a pH of 6.0-8.0 (particularly 6.5-7.5, such as 7.2), and an osmotic pressure of 500-650 mOsm / kg; more specifically, the phosphate buffer consists of disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride and water.
[0020] In some preferred embodiments of the present invention, the phosphate buffer comprises disodium hydrogen phosphate and potassium dihydrogen phosphate, has a pH of 6.0-8.0 (particularly 6.5-7.5, for example 7.2), and an osmotic pressure of 300-700 mOsm / kg (particularly 600 mOsm / kg); specifically, the phosphate buffer consists of disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride and water; more specifically, the phosphate buffer can be compounded by disodium hydrogen phosphate (Na2HPO4), potassium dihydrogen phosphate (KH2PO4) and potassium chloride aqueous solution.
[0021] In some preferred embodiments of the present invention, the phosphate buffer comprises dipotassium hydrogen phosphate and potassium dihydrogen phosphate, has a pH of 6.0-8.0 (particularly 6.5-7.5, such as 7.2), and an osmotic pressure of 500-650 mOsm / kg; more specifically, the phosphate buffer consists of dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride and water.
[0022] Specifically, the average particle size of the PCL microspheres is in the range of 25-60 μm (eg, 25, 30, 35, 40, 45, 50, 55, 60 μm).
[0023] Specifically, the PCL microspheres have a particle size of 25-50 μm and account for ≥65%.
[0024] Specifically, the weight average molecular weight of the PCL microspheres is 80,000-80,000 Da (e.g., 10,000 Da, 20,000 Da, 30,000 Da, 40,000 Da, 45,000 Da, 60,000 Da, 80,000 Da), particularly 10,000-60,000 Da.
[0025] Specifically, in the polycaprolactone microsphere pre-dispersed composition, the content of the PCL microspheres can be 10-50 wt% (e.g., 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%).
[0026] Specifically, the PCL microspheres can be prepared by the following method:
[0027] (1) Aqueous phase preparation: using a solution containing one or more of a film-forming agent, a surfactant, and a thickener as the aqueous phase;
[0028] (2) Oil phase preparation: Dissolve dry PCL in an organic solvent;
[0029] (3) preparing microspheres;
[0030] (4) The organic solvent in the emulsion evaporates, and the microspheres are solidified, filtered, washed, collected, and dried.
[0031] Specifically, the film-forming agent includes but is not limited to: polyvinyl alcohol, polypropylene alcohol, gelatin, gum arabic, dextran sulfate, hyaluronic acid, pectin, carrageenan, etc.
[0032] Specifically, the surfactant includes but is not limited to Tween, Span, sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, etc.
[0033] Specifically, the thickener includes but is not limited to gelatin, starch, carrageenan, sodium alginate, chitosan, fructose, sodium carboxymethyl cellulose, high-substituted hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, and the like.
[0034] Specifically, the organic solvent is selected from benzyl alcohol, dichloromethane, chloroform, ethyl chloride, dichloroethane, trichloroethane, ethyl acetate, ethyl formate, ether, cyclohexane or a mixed solvent thereof.
[0035] Specifically, the preparation of microspheres in step (3) can be carried out by a method known in the prior art, such as a membrane emulsification method and a spray drying method. For example, the microspheres can be prepared by a membrane emulsification method: a pressure of 800-10000 MPa, preferably 800-3500 MPa; more preferably 1000-2000 MPa is used to squeeze the oil phase through a membrane tube with a membrane pore of 5-100 μm, and squeezed into a continuous aqueous phase with an aqueous phase flow rate of 50-10000 ml / min; the D50 of the prepared microspheres can vary from 1 to 100 μm; the span is ≤2.0; the density, composition, and morphology are uniform; the appearance is spherical and the surface is smooth.
[0036] In some embodiments of the present invention, the PCL microspheres are prepared by the following method: preparing an aqueous phase, preparing polycaprolactone into an oil phase with dichloromethane, emulsifying the aqueous phase and the oil continuous phase, and vacuum drying to obtain polycaprolactone microspheres; the aqueous phase includes one or more of polyvinyl alcohol, carboxymethyl cellulose, sodium carboxymethyl cellulose, Tween 80, gelatin, hydroxypropyl cellulose starch, and sodium lauryl sulfate.
[0037] Specifically, the PCL microspheres can be sterile.
[0038] In a second aspect of the present invention, a method for preparing a pre-dispersed polycaprolactone microsphere composition is provided, comprising the step of (uniformly) dispersing dried polycaprolactone microspheres in a dispersion liquid, wherein the dispersion liquid is a phosphate buffer. The dispersion liquid for the polycaprolactone microspheres is typically purified water, distilled water, physiological saline, or the like. The inventors have discovered that using a phosphate buffer as the dispersion liquid helps maintain optimal dispersibility of the polycaprolactone microspheres and reduces the generation of bubbles.
[0039] Specifically, the polycaprolactone microspheres and phosphate buffer have the definitions described in the first aspect of the present invention.
[0040] In a third aspect of the present invention, there is provided a polycaprolactone gel for injection, which is prepared by a method comprising the steps of mixing the pre-dispersed composition described in the first aspect with a gel matrix, wherein the gel matrix comprises carboxymethyl cellulose (sodium) (i.e., carboxymethyl cellulose or sodium carboxymethyl cellulose) and a dispersion.
[0041] Specifically, the polycaprolactone gel for injection is prepared by a method comprising adding the pre-dispersed composition described in the first aspect into a gel matrix and mixing.
[0042] Specifically, the dispersion liquid of the gel matrix is selected from: water (such as distilled water, purified water, water for injection), physiological saline, and phosphate buffer.
[0043] In a preferred embodiment of the present invention, the dispersion liquid of the gel matrix is a phosphate buffer, in particular the phosphate buffer described in the first aspect of the present invention.
[0044] Specifically, the high content of polycaprolactone microspheres in the polycaprolactone injection gel means that the content of polycaprolactone microspheres is higher than 20%, preferably higher than 25%, and more preferably higher than 30%.
[0045] Specifically, in the polycaprolactone injection gel, the content of polycaprolactone microspheres is 28-38 wt % (eg, 28%, 30%, 32%, 33%, 34%, 36%, 38%), especially 30-36%.
[0046] Specifically, in the polycaprolactone gel for injection, the content of carboxymethyl cellulose (sodium) is 1-5 wt% (eg, 2 wt%, 2.3 wt%, 2.6 wt%, 2.9 wt%, 3 wt%, 4 wt%).
[0047] Specifically, the polycaprolactone gel for injection may further contain a pH regulator, such as one or more of hydrochloric acid, sodium hydroxide, potassium hydroxide, and the like.
[0048] Specifically, the pH of the polycaprolactone injection gel is 6.0-8.0 (e.g., 6.0, 6.2, 6.4, 6.5, 6.6, 6.8, 7.0, 7.2, 7.4, 7.5, 7.6, 7.8, 8.0), particularly 6.5-8.0, preferably 7.0-7.5.
[0049] Specifically, the polycaprolactone injection gel may further contain an osmotic pressure regulator, such as one or more of potassium chloride, sodium chloride, glycerol, and the like.
[0050] Specifically, the osmotic pressure of the polycaprolactone injection gel is 300-600 mOsm / kg (e.g., 300, 350, 400, 450, 500, 550, 600 mOsm / kg), particularly 500-650 mOsm / kg, preferably 550-650 mOsm / kg.
[0051] Specifically, the polycaprolactone injection gel may further contain an anesthetic, such as lidocaine, tetracaine, and the like.
[0052] Specifically, the polycaprolactone injection gel may further contain a lubricant, for example, glycerol.
[0053] Specifically, the polycaprolactone injection gel may further contain an antibacterial agent to enhance the antibacterial effect, thereby improving the antibacterial effect of the polycaprolactone injection gel during use, storage, and transportation.
[0054] Specifically, the polycaprolactone injection gel may further contain an anti-inflammatory agent to reduce the body's inflammatory response.
[0055] Specifically, the polycaprolactone gel for injection may further contain an antioxidant to improve the anti-oxidative property.
[0056] In a fourth aspect of the present invention, a method for preparing a polycaprolactone injection gel is provided, comprising the following steps:
[0057] (1) dispersing polycaprolactone microspheres (uniformly) in dispersion liquid I to obtain a polycaprolactone pre-dispersed composition;
[0058] (2) dispersing carboxymethyl cellulose (sodium) in dispersion II to obtain a gel matrix;
[0059] (3) Add the polycaprolactone pre-dispersed composition into the gel matrix and mix (evenly).
[0060] Specifically, the dispersion liquid I is a phosphate buffer, as described in the first aspect of the present invention.
[0061] Specifically, the dispersion II is selected from: water (such as distilled water, purified water, water for injection), physiological saline, phosphate buffer, especially the phosphate buffer described in the first aspect of the present invention.
[0062] Specifically, the dispersion I and the dispersion II can be the same phosphate buffer. For example, in some preferred embodiments of the present invention, the phosphate buffer comprises disodium hydrogen phosphate and sodium dihydrogen phosphate, and has a pH of 6.0-8.0 (especially 6.5-7.5, such as 7.2), and an osmotic pressure of 500-650 mOsm / kg; more specifically, the phosphate buffer consists of disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride and water; in other preferred embodiments of the present invention, the phosphate buffer comprises disodium hydrogen phosphate and potassium dihydrogen phosphate, and has a pH of 6.0-8.0 (especially 6.5-7.5, for example 7.2), and an osmotic pressure of 300-700 mOsm / kg (especially 600 mOsm / kg); specifically, the phosphate buffer consists of disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride and water; in other preferred embodiments of the present invention, the phosphate buffer contains dipotassium hydrogen phosphate and potassium dihydrogen phosphate, and has a pH of 6.0-8.0 (especially 6.5-7.5, for example 7.2), and an osmotic pressure of 500-650 mOsm / kg; more specifically, the phosphate buffer consists of dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride and water.
[0063] Specifically, step (1) may further include a step of adjusting pH.
[0064] Specifically, step (1) may further include a step of adjusting the osmotic pressure.
[0065] Specifically, step (1) may also include a sterilization step.
[0066] Specifically, step (2) may further include a step of adjusting pH.
[0067] Specifically, step (2) may further include a step of adjusting the osmotic pressure.
[0068] Specifically, step (2) may also include a sterilization step.
[0069] Specifically, the mixing method in step (3) is stirring, the stirring speed can be 800-1200 r / min (for example, 1000 r / min), and the stirring time can be 1-10 minutes (for example, 5 minutes).
[0070] Specifically, step (3) also includes a degassing step, for example, performing degassing by stirring using a vacuum stirring degassing machine.
[0071] In a fifth aspect of the present invention, there is provided use of the polycaprolactone pre-dispersed composition of the first aspect in the preparation of polycaprolactone injection gel, implants, and drug carriers.
[0072] In one embodiment of the present invention, the implant is a cosmetic implant, such as a subcutaneous implant (e.g., implanted in the forehead, nasolabial folds, mid-face, nose, jaw, hand, etc. to reduce wrinkles, folds, scars, aging, etc.); in some embodiments of the present invention, the implant is a dermal filler.
[0073] In another embodiment of the present invention, the implant is an implant for treating a disease, such as a stent.
[0074] The polycaprolactone microsphere pre-dispersed composition of the present invention has the following beneficial effects:
[0075] PCL microspheres maintain their spherical shape, smooth surface, and excellent dispersibility, reducing degradation rates and air bubbles during mixing, thus ensuring stable product quality and minimizing the risk of nodules and granulomas caused by uneven dispersion of microspheres after injection. Polycaprolactone injectable gels prepared using PCL microspheres have enhanced application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0076] Figure 1 shows a micrograph of undispersed, dry polycaprolactone microspheres.
[0077] Figure 2 shows a micrograph of polycaprolactone microspheres after dispersion in distilled water.
[0078] Figure 3 shows an electron microscope photograph of polycaprolactone microspheres after dispersion in distilled water.
[0079] FIG4 shows a micrograph of polycaprolactone microspheres dispersed in 0.9% saline.
[0080] FIG5 shows an electron microscope photograph of polycaprolactone microspheres dispersed in 0.9% saline.
[0081] FIG6 shows a micrograph of polycaprolactone microspheres dispersed in sodium isotonic phosphate buffer 3-2.
[0082] FIG7 shows an electron microscopic photograph of polycaprolactone microspheres dispersed in sodium isotonic phosphate buffer 3-2.
[0083] FIG8 shows a micrograph of polycaprolactone microspheres dispersed in isotonic phosphate buffer 3-5 containing potassium 1.
[0084] FIG9 shows an electron micrograph of polycaprolactone microspheres dispersed in isotonic phosphate buffer 3-5 containing potassium ion.
[0085] FIG10 shows a micrograph of polycaprolactone microspheres dispersed in isotonic phosphate buffer 3-8 containing potassium 2.
[0086] FIG11 shows an electron microscopic photograph of polycaprolactone microspheres dispersed in isotonic phosphate buffer 3-8 containing potassium 2.
[0087] FIG12 shows a micrograph of polycaprolactone microspheres dispersed in a sodium-based buffer solution (4-1-6) having an osmotic pressure of 600 mOsm / kg.
[0088] FIG13 shows a micrograph of polycaprolactone microspheres dispersed in a potassium-based buffer (4-2-6) having an osmotic pressure of 600 mOsm / kg.
[0089] FIG14 shows a micrograph of polycaprolactone microspheres dispersed in a potassium-based buffer (4-3-6) having an osmotic pressure of 600 mOsm / kg.
[0090] FIG15 shows an electron micrograph of polycaprolactone microspheres dispersed in a potassium-based buffer solution (4-2-6) having an osmotic pressure of 600 mOsm / kg.
[0091] FIG16 is a photograph showing the appearance of the injectable gel containing polycaprolactone microspheres of Example 11.
[0092] FIG17 is a micrograph of the injectable gel containing polycaprolactone microspheres of Example 11.
[0093] FIG18 is a photograph showing the appearance of the injectable gel containing polycaprolactone microspheres of Example 12 after stirring at 1000 r / min.
[0094] FIG19 is a photograph showing the appearance of the injectable gel containing polycaprolactone microspheres of Example 12 after stirring at 2200 r / min.
[0095] FIG20 shows a micrograph of the injectable gel containing polycaprolactone microspheres of Example 12 after stirring at 2200 r / min.
[0096] FIG21 is a photograph showing the appearance of the injectable gel containing polycaprolactone microspheres of Example 13 after stirring at 1000 r / min.
[0097] FIG22 is a photograph showing the appearance of the injectable gel containing polycaprolactone microspheres of Example 13 after stirring at 2200 r / min. DETAILED DESCRIPTION
[0098] Unless otherwise defined, all scientific and technical terms used in the present invention have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention relates.
[0099] The disclosures of various publications, patents, and published patent specifications cited herein are incorporated by reference in their entirety.
[0100] The following will clearly and completely describe the technical solutions of the present invention in conjunction with the embodiments of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts shall fall within the scope of protection of the present invention.
[0101] The specific operations of some detection methods used in the following examples are as follows:
[0102] Detection of morphology and particle size of dried microspheres
[0103] Take an appropriate amount of dried microspheres, cut about 0.5 cm of conductive tape, and stick it to the sample plate. Scrape a small amount of powder and stick it on the conductive tape. Use an ear bulb to blow away the excess powder on the conductive tape, spray gold, and place the sample stage into the instrument for observation. Use a thermal field emission scanning electron microscope (such as: JEOL-JSM-7001F, Japan Electronics) to take electron microscope photos.
[0104] Take a small amount of dried microspheres and disperse them with dispersion liquid, stir at high speed or ultrasonicate for 10 minutes, add them dropwise to a quartz dish after the microspheres are completely dispersed, and measure the particle size distribution of the microspheres with a Zeta particle size analyzer.
[0105] Detection of microsphere morphology and particle size after dispersion
[0106] A small amount of dried microspheres was dispersed with a dispersion solution, stirred at high speed or ultrasonicated for 10 min, and the dispersion of microspheres and bubble formation were observed under a microscope (XP-550C polarizing microscope).
[0107] Take a small amount of dried microspheres and disperse them with dispersion liquid, stir at high speed or ultrasonicate for 10 minutes, add them dropwise to a quartz dish after the microspheres are completely dispersed, and measure the particle size distribution of the microspheres with a Zeta particle size analyzer.
[0108] Detection of microsphere degradation in dispersion
[0109] Six PCL microspheres of equal mass were weighed (W0) and immersed in distilled water dispersion, placed in a shaker at 37°C at 60 r / min. The dispersion was replaced weekly, and the degradation period was 8 weeks, and the measurement was performed for 48 weeks. At the end of each degradation period, the samples were removed, rinsed thoroughly with distilled water, and freeze-dried in a vacuum oven to a constant weight (W0). t ). Calculate the degradation rate = (W0-W t ) / W0×100%.
[0110] Detection of degradation of microspheres in gel
[0111] Six equal-weight PCL microspheres (W0) were weighed and mixed in distilled water as dispersions to prepare corresponding carboxymethyl cellulose (or sodium carboxymethyl cellulose) gels. The gels were shaken at 60 rpm at 37°C. Degradation was measured over 48 weeks, with each degradation period consisting of 8 weeks. At the end of each degradation period, one sample was removed, the microspheres collected by centrifugation, rinsed thoroughly with distilled water, and freeze-dried under vacuum to a constant weight (Wt). The degradation rate of PCL microspheres in the gels prepared from the dispersions was calculated as (W0 - Wt) / W0 × 100%.
[0112] The measurement of the degradation rate in the carboxymethyl cellulose (or sodium carboxymethyl cellulose) gel prepared with 0.9% saline or PBS as the dispersion liquid is the same as the preparation and measurement process of the above-mentioned distilled water as the dispersion liquid.
[0113] 1. Preparation of dry polycaprolactone microspheres:
[0114] Example 1
[0115] 10 to 20 grams of PCL (8 kDa Mw) were dissolved in dichloromethane (DCM, 10-20 w / w%). This solution was then dispersed in 1000 ml of water containing 0.1% to 5% MC. Solvent extraction was performed with stirring (1000 rpm). The resulting microspheres were filtered, washed, and dried. Microspheres with an average diameter of 40 μm were obtained, with 68.6% of the PCL microspheres having a particle size of 25-50 μm. The span was 1.18, resulting in a yield of approximately 67%.
[0116] Example 2
[0117] 53.9 g of PCL (with a Mw of 10,000 Da) was weighed and dissolved in dichloromethane (DCM, viscosity 700 cp). Using membrane emulsification at a pressure of 800 MPa, the oil phase solution was dispersed into a high-speed shear solution containing a 1% aqueous solution of polyvinyl alcohol, a 0.1% aqueous solution of Tween 80, and a 2.2% aqueous solution of sodium carboxymethylcellulose. The resulting microspheres were filtered, washed, and dried. The average microsphere diameter was approximately 50 μm, with 70.4% of the PCL microspheres having a particle size of 25-50 μm. The span was 1.19, and the yield was approximately 70%.
[0118] Example 3
[0119] 54.9 g of PCL (40,000 Da in Mw) was weighed and dissolved in dichloromethane (DCM, viscosity 800 cp). Using a high-speed homogenization emulsifier, the oil phase solution was dispersed into a high-shear aqueous solution containing (1%) polyvinyl alcohol, (0.5%) gelatin, and (3.7%) sodium carboxymethylcellulose. The resulting microspheres were filtered, washed, and dried. The average microsphere diameter was approximately 55 μm, with 65.6% of the PCL microspheres having a particle size of 25-50 μm. The span was 1.19, and the yield was approximately 65%.
[0120] Example 4
[0121] 54.9 g of PCL (60,000 Da in Mw) was dissolved in dichloromethane (DCM, viscosity 800 cp). The oily solution was dispersed into a high-shear aqueous solution containing 1% polyvinyl alcohol and 2.2% hydroxypropyl cellulose using a membrane emulsification method at 800 MPa. The resulting microspheres were filtered, washed, and dried. The average microsphere diameter was approximately 60 μm, with 66.2% of the PCL microspheres having a particle size of 25-50 μm. The span was 1.19, resulting in a yield of approximately 55%.
[0122] Example 5
[0123] 53.9 g of PCL (80,000 Da in Mw) was dissolved in dichloromethane (DCM, viscosity 700 cp). The oily solution was dispersed into a high-speed shear solution containing 1% polyvinyl alcohol, 0.1% sodium lauryl sulfate, and 2.2% sodium carboxymethylcellulose using a membrane emulsification method at 800 MPa. The resulting microspheres were filtered, washed, and dried. The average microsphere diameter was approximately 50 μm, with 73.3% of the PCL microspheres having a particle size of 25-50 μm. The span was 1.19, resulting in a yield of approximately 70%.
[0124] 2. Dispersion of dry polycaprolactone microspheres:
[0125] The following examples used PCL microspheres prepared in Example 2 to investigate the effects of different dispersion solutions on the dispersion, bubble content, and smoothness of the resulting PCL microspheres. A micrograph of the undispersed microspheres (XP-550C polarizing microscope, 10x magnification) is shown in Figure 1, showing agglomeration of the microspheres.
[0126] Example 6: Dispersion 1 (distilled water)
[0127] The resulting microspheres were dispersed in distilled water and the PCL surface smoothness, spherical integrity, and dispersion were observed under a microscope and electron microscope. Microscopic photographs (XP-550C polarizing microscope, 10x) and electron microscope photographs of the PCL microspheres are shown in Figures 2 and 3, respectively.
[0128] As shown in Figure 2, the microspheres were not well dispersed in distilled water.
[0129] As shown in Figure 3, the surface smoothness of the microspheres decreased and the spherical integrity was damaged.
[0130] Example 7: Dispersion 2 (0.9% saline)
[0131] The prepared microspheres were dispersed in 0.9% saline and the surface smoothness, spherical integrity, and dispersion of PCL were observed under a microscope and an electron microscope. Microscopic photos (XP-550C polarizing microscope 20x) and electron microscope photos of PCL microspheres are shown in Figures 4 and 5, respectively.
[0132] As shown in FIG4 , the dispersion of the microspheres in physiological saline is improved compared to distilled water, and as can be seen from the electron microscopy in FIG5 , the surface smoothness of the microspheres is less damaged and the spherical integrity is improved.
[0133] Example 8: Dispersion 3: (isotonic phosphate buffer with different pH values)
[0134] 1. Prepare sodium isotonic phosphate buffer:
[0135] Sodium hydrogen phosphate: 0.1 M sodium hydrogen phosphate (Na2HPO4), store at 4°C;
[0136] Sodium dihydrogen phosphate: 0.1M sodium dihydrogen phosphate (NaH2PO4 ● H2O).
[0137] Prepare a solution of the desired pH according to the following table:
[0138] Table 1 Dispersion formulation
[0139] The prepared microspheres were dispersed into the above-described dispersions 3-1 to 3-3. The PCL surface smoothness (smooth+++++; essentially smooth++++; slightly uneven+++; quite uneven++; quite uneven+), spherical integrity (spherical+++++; essentially spherical++++; 1-2 ellipsoidal vertices+++; 2-4 ellipsoidal vertices++; 5 or more ellipsoidal vertices+), and dispersion (no aggregation++++; essentially no aggregation++++; slightly aggregated+++; more than 3 microspheres aggregated++; quite a few aggregates of more than 3 microspheres aggregated+) were observed under a microscope and electron microscope. The results are shown in the table below. Microscopic photographs (XP-550C polarizing microscope, 10x) and electron microscope photographs of the PCL microspheres in dispersion 3-2 are shown in Figures 6 and 7, respectively.
[0140] Table 2 Investigation results of dispersion
[0141] As shown in Figures 6-7 (corresponding to dispersion 3-2) and the table above, the dispersion of the microspheres in the sodium-based isotonic phosphate buffer is further improved, and as can be seen from the electron microscopy photos, the surface smoothness of the microspheres is less damaged and the spherical integrity is improved.
[0142] 2. Prepare isotonic phosphate buffer solution containing potassium 1:
[0143] Sodium hydrogen phosphate: 0.1 M sodium hydrogen phosphate (Na2HPO4), store at 4°C;
[0144] Potassium dihydrogen phosphate: 0.1 M potassium dihydrogen phosphate (KH2PO4), store at 4°C.
[0145] Prepare a solution of the desired pH according to the following table:
[0146] Table 3 Dispersion formulation
[0147] The prepared microspheres were dispersed into Dispersions 3-4 to 3-6 described above. The PCL surface smoothness, spherical integrity, and dispersion were observed under a microscope and electron microscope. The results are shown in the table below. Microscopic photographs (XP-550C polarizing microscope, 10x) and electron microscope images of the PCL microspheres in Dispersions 3-5 are shown in Figures 8 and 9, respectively.
[0148] Table 4 Investigation results of dispersion
[0149] As shown in Figures 8-9 (corresponding to dispersions 3-5) and the table above, the dispersion of the microspheres in the isotonic phosphate buffer of potassium series 1 is further improved, and as can be seen from the electron microscopy photos, the surface smoothness of the microspheres is slightly damaged and the spherical integrity is high.
[0150] 3. Prepare isotonic phosphate buffer solution containing potassium 2:
[0151] Potassium hydrogen phosphate (divalent): 0.1 M potassium hydrogen phosphate (K2HPO4), store at 4°C;
[0152] Potassium dihydrogen phosphate: 0.1 M potassium dihydrogen phosphate (KH2PO4), store at 4°C.
[0153] Prepare a solution of the desired pH according to the following table:
[0154] Table 5 Dispersion formulation
[0155] The prepared microspheres were dispersed into Dispersions 3-7 to 3-9 described above. The PCL surface smoothness, spherical integrity, and dispersion were observed under a microscope and electron microscope. The results are shown in the table below. Microscopic photographs (XP-550C polarizing microscope, 10x) and electron microscope images of the PCL microspheres in Dispersion 3-8 are shown in Figures 10 and 11, respectively.
[0156] Table 6 Investigation results of dispersion
[0157] As shown in Figures 10-11 (corresponding to dispersions 3-8) and the table above, the microspheres have good dispersion in the isotonic phosphate buffer of potassium series 2 and the sodium series dispersion, and the electron microscopy photos show that the surface smoothness of the microspheres is slightly damaged and the spherical integrity is high.
[0158] Example 9: Dispersion 4 (Phosphate Buffers of Different Osmolarities)
[0159] 1. Prepare buffer solutions of different osmotic values (pH 7.2, 100 ml) based on sodium-based isotonic phosphate buffer.
[0160] With reference to dispersion 3-2 in Table 2 of Example 8, the osmotic pressure was adjusted by adjusting the amount of NaCl added to obtain dispersions 4-1-1 to 4-1-8.
[0161] The prepared microspheres were dispersed in the above dispersions 4-1-1 to 4-1-8. The surface smoothness, spherical integrity, and dispersion of the PCL were observed under a microscope and electron microscope. The results are shown in the table below.
[0162] Table 7 Investigation results of dispersion
[0163] 2. Prepare buffer solutions of different osmotic pressures (pH 7.2, 100 ml) based on the isotonic phosphate buffer solution of potassium series 1.
[0164] Referring to dispersion 3-5 in Table 3 of Example 8, the osmotic pressure was adjusted by adjusting the amount of KCl added to obtain dispersions 4-2-1 to 4-2-8.
[0165] The prepared microspheres were dispersed in the above dispersions 4-2-1 to 4-2-8. The surface smoothness, spherical integrity, and dispersion of the PCL were observed under a microscope and electron microscope. The results are shown in the table below.
[0166] Table 8 Investigation results of dispersion
[0167] 3. Prepare buffer solutions of different osmotic values (pH 7.2, 100 ml) based on the isotonic phosphate buffer solution of potassium series 2.
[0168] Referring to dispersions 3-8 in Table 5 of Example 8, the osmotic pressure was adjusted by adjusting the amount of KCl added to obtain dispersions 4-3-1 to 4-3-8.
[0169] The prepared microspheres were dispersed in dispersions 4-3-1 to 4-3-8 above. The PCL surface smoothness, spherical integrity, and dispersion were observed under a microscope (XP-550C polarizing microscope 10x) and an electron microscope. The results are shown in the table below.
[0170] Table 9 Investigation results of dispersion
[0171] As shown in Figures 12-14 (corresponding to dispersions 4-1-6, 4-2-6, and 4-3-6, respectively) and the table above, compared with dispersions of other osmotic pressures of sodium, potassium 2, and potassium 1, the microspheres dispersed in the buffer solution with an osmotic pressure of 600 of potassium 1 have good dispersion, minimal damage to the surface smoothness of the microspheres, and no effective change in the spherical integrity.
[0172] Example 10: Effect of dispersion on microsphere degradation
[0173] Weigh 18 portions (750 mg, W0) of PCL microspheres (PCL weight-average molecular weight 40,000). Six portions were immersed in 10 mL of distilled water, 10 mL of 0.9% saline, and 10 mL of PBS (dispersion 4-2-6 described in Example 9). The samples were shaken at 37°C at 60 rpm. The solution was changed weekly. Degradation was measured for 48 weeks, with each period consisting of 8 weeks. At the end of each degradation period, samples were removed, rinsed thoroughly with distilled water, and freeze-dried under vacuum to a constant weight (Wt). Degradation rate = (W0 - Wt) / W0 × 100%.
[0174] Table 10 Degradation rate investigation results
[0175] As shown in the table above, the degradation rate of PCL pre-dispersed with PBS (dispersion 4-2-6 described in Example 9) was lower than that of saline and significantly lower than that of distilled water. This suggests that PBS as a dispersion liquid can effectively reduce PCL degradation, and maintaining the smooth spherical shape of the microspheres helps reduce the degradation rate of the microspheres.
[0176] 3. Preparation of polycaprolactone microsphere gel
[0177] Example 11:
[0178] Preparation of polycaprolactone microspheres for injection gel, the specific steps are as follows:
[0179] (1) CMC and deionized water were stirred and mixed uniformly to obtain a CMC suspension; sodium hydroxide solution was added to the CMC suspension and mixed uniformly; then hydrochloric acid was added to adjust the pH value to neutral to obtain CMC-Na gel, and 33 g of CMC-Na gel was measured;
[0180] (2) Prepare the dispersion 4-2-6 described in Example 9 of the phosphate buffer solution;
[0181] (3) Dispersing 33 g of sterilized PCL microspheres into 33 g of a dispersion solution containing a phosphate buffer solution having a pH of approximately 7 at a stirring speed of 500 rpm to form a uniform pre-dispersed composition;
[0182] (4) adding the pre-dispersed composition to the CMC-Na gel (the content of CMC-Na in the final product is 2.6 wt.%), adding glycerol accounting for 1 wt.% of the product, and performing preliminary stirring for 5 min using a glass rod or a fine spatula;
[0183] (5) Prepare the preliminarily mixed sample and use a vacuum stirring degassing machine to stir and remove bubbles for 6 minutes at a speed of 1000 r / min. The amount of PCL in the final product is 33 wt.%.
[0184] Example 12: (Comparative Product 1): PCL microspheres were directly added to the CMC-Na gel without preparing a pre-dispersed composition.
[0185] Preparation of polycaprolactone microspheres for injection gel, the specific steps are as follows:
[0186] (1) Dissolve 2.6 g of CMC-Na powder in 63.4 g of the phosphate buffer prepared in Example 11 to form a gel;
[0187] (2) Add 33 g of sterilized PCL microspheres to CMC-Na gel (the content of CMC-Na in the final product is 2.6 wt.%), add 1 wt.% of glycerol to the product, and stir initially for 5 min using a glass rod or fine spatula;
[0188] (3) Prepare the preliminarily mixed sample and use a vacuum stirring degasser to stir and remove bubbles for 6 minutes at a speed of 1000 r / min. The final product contains 33 wt.% PCL. The speed is then increased to 2200 r / min for 10 minutes.
[0189] Example 13: (Comparative Product 2): PCL microspheres, CMC-Na powder, phosphate buffer and glycerol were directly mixed without preparing a pre-dispersed composition.
[0190] Preparation of polycaprolactone microspheres for injection gel, the specific steps are as follows:
[0191] (1) 33 g of PCL microspheres, 63.4 g of phosphate buffer prepared by the method of Example 11, and 1 g of glycerol were stirred at a speed of 500 r / min to form a uniform suspension;
[0192] (2) Place 2.6 g of CMC-Na powder in a container, add a suspension consisting of PCL microspheres, phosphate buffer, and 1 g of glycerol to the container, and stir the mixture for 5 minutes using a glass rod or a fine spatula.
[0193] (3) Prepare the preliminarily mixed sample and use a vacuum stirring degassing machine to stir and remove bubbles for 5 minutes at a speed of 1000 r / min. The final product contains 33 wt.% PCL. The speed is then increased to 2200 r / min for 10 minutes.
[0194] Example 14: Comparison of a gel product without microspheres and a product in which PCL microspheres are directly added to CMC-Na gel
[0195] 2.6 g of CMC-Na powder was dissolved in 96.4 g of the phosphate buffer prepared in Example 11, and 1 wt % of glycerol was added to form a gel (the content of CMC-Na in the gel was 2.6 wt %).
[0196] The physical and chemical properties of the above-mentioned microsphere-free gel and the CMC-Na gel containing microspheres prepared in Example 12 were compared, and the results are shown in the following table.
[0197] Table 11 Shear viscosity comparison results
[0198] It can be seen from the above table that after adding PCL microspheres to CMC-Na gel, the shear viscosity of the polycaprolactone gel for injection formed is significantly increased. At this time, the gel is more viscous and it is more difficult to mix evenly. The mixing method for high-viscosity fluids in the prior art generally adopts the high-speed shear mixer as described above, or other mixing methods such as a high-viscosity homogenizer. However, in this process, the CMC gel will entrap bubbles and bring additional heat to the system, causing the microspheres in the injectable gel to shrink and deform, affecting the injection effect. Therefore, in Example 11, the method of adding a PCL microsphere pre-dispersed composition to the CMC gel is adopted to reduce the viscosity of the microspheres when mixed with the CMC-Na gel, reduce bubbles and improve mixing efficiency.
[0199] Example 15: Comparison of Bubble and Microsphere Dispersibility of Gel Products in Examples 11-13
[0200] The bubbles (no bubbles -; scattered bubbles +; a small amount of bubbles ++; more bubbles +++; a large amount of bubbles ++++; all bubbles +++++) and microsphere dispersibility of the product prepared in Example 11 were compared with those of the comparative products 1-2 prepared in Examples 12-13. The results are shown in the following table.
[0201] Table 12 Bubble and microsphere dispersion results of gel products in Examples 11-13
[0202] As can be seen from the microscope photo (BM2000 microscope 10x) Figure 16, compared with the control product, the bubbles in the gel product are greatly reduced after using the pre-dispersed composition. As can be seen from the microscope photo (XP-550C polarizing microscope 10x) Figure 17, a gel product with uniform distribution of PCL microspheres can be obtained by using a mixing speed of 1000 r / min for 5 minutes; while the control product still needs to increase the speed and time for continued stirring.
[0203] Without the pre-dispersion step, both Comparative Products 1 and 2 produced a significant number of bubbles during stirring (the larger black spheres with white centers in Figures 18 and 21 represent bubbles). This was particularly true in Comparative Product 2, where PCL microspheres, CMC-Na powder, phosphate buffer, and glycerol were directly mixed. Furthermore, insufficient mixing of the CMC-Na resulted in numerous white clumps. Stirring at 1000 rpm for 5 minutes was insufficient, making further mixing of the CMC aggregates to produce a uniform gel-like injection difficult.
[0204] From Figure 20 of Comparative Product 1 (XP-550C polarizing microscope 10x), it can be seen that the gel contains a large number of bubbles and some microspheres are agglomerated. Its dispersion effect is similar to that using deionized water as the dispersion liquid, and both have certain aggregation and difficulty in dispersion.
[0205] We attempted to continue processing the gel at a higher speed and longer stirring time. In Comparative Product 1, after increasing the speed to 2200 r / min for 10 minutes, as shown in Figure 19, the gel showed improved uniformity and transparency, with large bubbles dispersed into smaller ones, though their number remained high. In Comparative Product 2, after the same treatment at a higher speed, a large number of bubbles remained. While agglomeration and clumping were slightly reduced, the overall dispersion of the gel remained uneven and inferior to that of the further treated sample in Example 12.
[0206] Example 16: Effect of gel matrix on microsphere degradation
[0207] Six 750 mg portions (W0) of PCL microspheres (PCL weight-average molecular weight 40,000 Da) were weighed and mixed into distilled water, then into a sodium carboxymethylcellulose gel. The mixture was shaken at 60 rpm at 37°C. Degradation was measured over 48 weeks, with each degradation period consisting of 8 weeks. At the end of each degradation period, a sample was removed, the microspheres collected by centrifugation, rinsed thoroughly with distilled water, and freeze-dried under vacuum to a constant weight (Wt). The degradation rate of PCL microspheres in the distilled water-based gel was then determined.
[0208] The degradation rate in the sodium carboxymethylcellulose gel prepared using 0.9% saline and PBS (dispersion 4-2-6 described in Example 9) after adjusting the osmotic pressure with KCl was the same as the preparation and measurement process of the above-mentioned distilled water dispersion.
[0209] Table 14 Degradation rate investigation results
[0210] As shown in the table above, the PCL degradation rate in the gel prepared using PBS (dispersion 4-2-6 described in Example 9) as a dispersion was lower than that of saline and significantly lower than that of distilled water. This suggests that PBS as a dispersion can effectively reduce PCL degradation, and maintaining the smooth spherical shape of the microspheres helps reduce the degradation rate of the microspheres.
[0211] The above studies show that using phosphate buffer as the dispersion liquid, especially the buffer prepared from disodium hydrogen phosphate and potassium dihydrogen phosphate as the dispersion liquid, with a pH of 6.0-8.0 and an osmotic pressure of 300-650mOsm / kg, can well maintain the smooth spherical morphology of the surface of PCL microspheres and reduce or avoid the generation of bubbles. Furthermore, using CMC-Na as the gel matrix and KCl as the osmotic pressure regulator, with an osmotic pressure of 300-650mOsm / kg, can well maintain the smooth spherical morphology of the surface of PCL microspheres and can effectively reduce the degradation of PCL microspheres.
[0212] The above is only a preferred embodiment of this patent. It should be pointed out that for ordinary technicians in this technical field, several improvements and substitutions can be made without departing from the technical principles of this patent. These improvements and substitutions should also be regarded as the scope of protection of this patent.
Claims
1. A polycaprolactone microsphere pre-dispersed composition comprising polycaprolactone microspheres and dispersion I; wherein: The dispersion I comprises a phosphate buffer, wherein the phosphate buffer comprises dihydrogen phosphate and / or dihydrogen phosphate, the pH of the dispersion I is 7.0-7.5, and the osmotic pressure is 550-650 mOsm / kg; The polycaprolactone microsphere pre-dispersed composition is prepared by uniformly dispersing dried polycaprolactone microspheres in dispersion liquid I.
2. The polycaprolactone microsphere pre-dispersed composition according to claim 1, wherein The dihydrogen phosphate is selected from one or more of disodium hydrogen phosphate, dipotassium hydrogen phosphate, and diammonium hydrogen phosphate, and the dihydrogen phosphate is selected from one or more of sodium dihydrogen phosphate, potassium dihydrogen phosphate, and ammonium dihydrogen phosphate.
3. The polycaprolactone microsphere pre-dispersed composition according to claim 2, wherein The dispersion I further comprises a pH adjuster.
4. The polycaprolactone microsphere pre-dispersed composition according to claim 3, wherein The pH regulator is selected from one or more of hydrochloric acid, sodium hydroxide and potassium hydroxide.
5. The polycaprolactone microsphere pre-dispersed composition according to claim 4, wherein The dispersion I further comprises an osmotic pressure regulator.
6. The polycaprolactone microsphere pre-dispersed composition according to claim 5, wherein The osmotic pressure regulator is selected from one or more of potassium chloride, sodium chloride and glycerol.
7. The polycaprolactone microsphere pre-dispersed composition according to claim 6, wherein the disodium hydrogen phosphate is disodium hydrogen phosphate; the dihydrogen phosphate is potassium dihydrogen phosphate; the osmotic pressure is replaced by 300-650 mOsm / kg; and the osmotic pressure regulator is potassium chloride.
8. The polycaprolactone microsphere pre-dispersed composition according to any one of claims 1 to 7, characterized in that The average particle size of the polycaprolactone microspheres is in the range of 25-60 μm, and the proportion of microspheres with a particle size of 25-50 μm in the polycaprolactone microspheres is ≥65%; the weight average molecular weight of the polycaprolactone microspheres is 8k-80,000 Da.
9. A polycaprolactone gel for injection, comprising the polycaprolactone microsphere pre-dispersed composition according to any one of claims 1 to 8 and a gel matrix, wherein the gel matrix comprises dispersion II and carboxymethyl cellulose or sodium carboxymethyl cellulose; The dispersion II of the gel matrix is selected from: water, physiological saline or phosphate buffer; The pH of the polycaprolactone gel for injection is 7.0-7.5, and the osmotic pressure is 550-650 mOsm / kg.
10. The polycaprolactone injection gel according to claim 9, wherein In the polycaprolactone gel for injection, the content of polycaprolactone microspheres is 28-38 wt %; the content of carboxymethyl cellulose or sodium carboxymethyl cellulose is 1-5 wt %.
11. A method for preparing the polycaprolactone injection gel as claimed in claim 9 or 10, comprising the following steps: (1) dispersing polycaprolactone microspheres into dispersion liquid I to obtain a polycaprolactone pre-dispersed composition; (2) dispersing carboxymethyl cellulose or sodium carboxymethyl cellulose in dispersion II to obtain a gel matrix; (3) adding the polycaprolactone pre-dispersed composition of step (1) into the gel matrix of step (2) and mixing.
12. Use of the polycaprolactone microsphere pre-dispersed composition according to any one of claims 1 to 8 in the preparation of polycaprolactone injection gel, implant, and drug carrier.
